CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology firm centered on unlocking the broad potential of RNA medicines to rework human well being, in the present day introduced that it’ll host a digital Analysis Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. As well as, members of Wave’s administration group are scheduled to take part in a number of upcoming investor conferences. Particulars are as follows:
Bernstein 2nd Annual Healthcare Discussion board
Date: Wednesday, September 24, 2025 at 2:50 p.m. ET
Particulars: Erik Ingelsson, MD, PhD, Chief Scientific Officer, will take part in an analyst-led hearth chat
Stifel Digital Cardiometabolic Discussion board
Date: Tuesday, September 30, 2025 at 1:00 p.m. ET
Particulars: Paul Bolno, MD, MBA, President and CEO, and Erik Ingelsson will take part in an analyst-led hearth chat
Chardan’s ninth Annual Genetic Medicines Convention
Date: Tuesday, October 21, 2025 at 1:00 p.m. ET
Particulars: Paul Bolno will take part in a panel discussing RNA modifying therapeutics
Wave’s 2025 Digital Analysis Day
Date: Wednesday, October 29, 2025 at 10:00 a.m. ET
Particulars: Extra particulars to comply with
Stay webcasts of those shows will be accessed by visiting “Investor Occasions” on the Buyers part of the Wave Life Sciences web site: https://ir.wavelifesciences.com/events-publications/events. Replays of those shows shall be archived and out there on the location for a restricted time following the occasion.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology firm centered on unlocking the broad potential of RNA medicines to rework human well being. Wave’s RNA medicines platform, PRISM®, combines a number of modalities, chemistry innovation and deep insights in human genetics to ship scientific breakthroughs that deal with each uncommon and customary problems. Its toolkit of RNA-targeting modalities consists of modifying, splicing, RNA interference and antisense silencing, offering Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally tackle illness biology. Wave’s diversified pipeline consists of medical applications in alpha-1 antitrypsin deficiency, weight problems, Duchenne muscular dystrophy, and Huntington’s illness, in addition to a number of preclinical applications using the corporate’s broad RNA therapeutics toolkit. Pushed by the calling to “Reimagine Potential”, Wave is main the cost towards a world through which human potential is now not hindered by the burden of illness. Wave is headquartered in Cambridge, MA. For extra data on Wave’s science, pipeline and folks, please go to www.wavelifesciences.com and comply with Wave on X (previously Twitter) and LinkedIn.
Contact:
Kate Rausch
VP, Company Affairs and Investor Relations
+1 617-949-4827
Buyers:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Company Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
